Nurix Therapeutics, Inc.

Nurix Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing targeted protein degradation medicines. Its pipeline includes wholly owned and partnered drug candidates for cancer and inflammatory diseases, built around its DEL-AI discovery engine and ligase expertise.

−329,8 %

−314,9 %

+54,0 %

7.02

7.02

— Nurix Therapeutics, Inc.
%
Wholly owned clinical-stage drug candidates0% Internal pipeline assets in clinical development for oncology and inflammatory disease.
Partnered discovery and development programs100% Programs advanced with pharmaceutical partners under collaboration and license agreements.
Preclinical degrader platform programs0% Earlier-stage degrader and DAC programs generated from the DEL-AI discovery engine.

Nurix’s direct counterparties are pharmaceutical partners that license, fund, or co-develop degrader programs,...

  • Pharmaceutical collaboration partnersprimary

    Large pharma companies that license targets or co-develop degrader programs under collaboration agreements.

  • Healthcare payors and reimbursement bodiesprimary

    Government and private payors that would reimburse approved products and influence uptake.

  • Oncology and immunology treatment providerssecondary

    Hospitals, clinics, and specialists that would prescribe or administer approved therapies.

  • Patients with cancer and inflammatory diseaseprimary

    The ultimate users of Nurix’s drug candidates if they are approved and commercialized.

Nurix is headquartered in Brisbane, California and operates as a U.S.-based biotechnology company...

  • •Headquartered in Brisbane, California, United States
  • •Core research and corporate operations are U.S.-based
  • •Trademark registrations span North America, Europe, and Japan
  • •Collaborations create exposure to global pharma markets
  • •Future commercialization would depend on U.S. and ex-U.S. approvals

Nurix’s strategy is to advance its lead degrader programs through clinical development while expanding the DEL-AI...

01
Advance lead clinical programsshort-term

Clinical proof-of-concept is the main value driver for a pre-commercial biotech.

02
Grow partnered discovery revenuemedium-term

Collaborations can offset R&D spend and validate the platform with major pharma partners.

03
Expand the protein degradation platformlong-term

A broader target base increases the chance of finding differentiated drug candidates.

Nurix faces the typical risks of a clinical-stage biotech: clinical failure, regulatory setbacks, manufacturing...

high

Clinical development failure

Drug candidates may not demonstrate sufficient safety or efficacy in trials.

Scope
Lead programs and partnered pipeline
Materiality
high
high

Regulatory delay or refusal

FDA or other agencies may require more data, impose holds, or reject filings.

Scope
All clinical-stage assets
Materiality
high
high

Manufacturing and supply chain disruption

Early-stage third-party manufacturing can face scale-up, quality, or contamination issues.

Scope
Clinical trial supply and future commercial supply
Materiality
high
high

Financing dependence

The company has no approved products and must fund long development timelines.

Scope
Corporate liquidity and program continuity
Materiality
high
medium

Competitive pressure

Other protein degradation, antibody, gene therapy, and small-molecule programs may reach market first.

Scope
BTK degrader and immunology/oncology targets
Materiality
medium
Revenue recognition for collaborations and licenses
Can cause uneven quarterly revenue
R&D accrual estimates
Affects operating expense and period comparability
Stock-based compensation
Raises reported operating expenses without cash outflow
Deferred tax asset valuation allowance
Limits recognition of tax benefits on the balance sheet

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

Immix Biopharma, Inc.

IMMX · Pharmaceutical Preparations

NRX Pharmaceuticals, Inc.

NRXP · Pharmaceutical Preparations

GRI Bio, Inc.

GRI · Pharmaceutical Preparations

NEKTAR THERAPEUTICS

NKTR · Pharmaceutical Preparations

Kezar Life Sciences, Inc.

KZR · Pharmaceutical Preparations

: 29/04/2026